Table 1 Characteristics of patients and tumours in the training, validation and control set

	Training		Validation		Control
Feature	N	%	N	%	N	%
	148		157		85
Gender
Male	121	82	135	86	78	91
Female	27	18	22	14	7	8
Median age (range) years	60 (34–78)		61 (31–80)		62 (37–79)
Tumour type
Squamous	44	30	44	28	17	20
Non-squamous	104	70	113	72	68	80
ECOG PS
0–1	127	86	135	86	80	94
2	21	14	21	14	5	6
Stage
IIIB (wet)	38	25	41	26	24	28
IV	110	75	116	74	61	72
Platinum-based first-line
Platinum+docetaxel	110	74	111	71	NA
Platinum+docetaxel+Avastin	18	12	22	14	NA
Platinum+gemcitabine	15	10	17	11	NA
Platinum+pemetrexed	5	4	7	4	NA
Non-platinum-based first-line
Docetaxel+gemcitabine	NA		NA		85	100
Post-progression treatment	100	68	105	67	55	65
EGFR mutational status
EGFR wt	27		34		10
EGFR mut	4		4		1
EGFR uknown	117		119		74
PKM2 mRNA expression
Median (range)	12.77 (0.34–71.88)		NA		12.73 (0.36–70.34)
High expression	74	50	78	49	42	49
Low expression	74	50	79	51	43	51

Abbreviations: ECOG PS=Eastern Cooperative Oncology Group Performance Status; NA=not applicable.

Quick links

Search